Cargando…

Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice

From the perspective of epidemiology, viral immunology and current clinical research, pulmonary fibrosis may become one of the complications of patients with Coronavirus Disease 2019 (COVID-19). Cytokine storm is a major cause of new coronavirus death. The purpose of this study was to explore the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hailong, Liu, Rui, Zhang, Ruotong, Zhang, Shanshan, Wei, Yiying, Zhang, Liang, Zhou, Honggang, Yang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873045/
https://www.ncbi.nlm.nih.gov/pubmed/33584285
http://dx.doi.org/10.3389/fphar.2020.607075
_version_ 1783649311221874688
author Li, Hailong
Liu, Rui
Zhang, Ruotong
Zhang, Shanshan
Wei, Yiying
Zhang, Liang
Zhou, Honggang
Yang, Cheng
author_facet Li, Hailong
Liu, Rui
Zhang, Ruotong
Zhang, Shanshan
Wei, Yiying
Zhang, Liang
Zhou, Honggang
Yang, Cheng
author_sort Li, Hailong
collection PubMed
description From the perspective of epidemiology, viral immunology and current clinical research, pulmonary fibrosis may become one of the complications of patients with Coronavirus Disease 2019 (COVID-19). Cytokine storm is a major cause of new coronavirus death. The purpose of this study was to explore the effects of antiviral drug arbidol on cytokine storm and pulmonary fibrosis. Here, we use a mouse model of bleomycin-induced pulmonary fibrosis and a mouse model of fecal dilution-induced sepsis to evaluate the effects of arbidol on pulmonary fibrosis and cytokine storm. The results showed that arbidol significantly reduced the area of pulmonary fibrosis and improved lung function (reduced inspiratory resistance, lung dynamic compliance and forced vital capacity increased). Treatment with arbidol promoted reduced sepsis severity 48 h after sepsis induction, based on weight, murine sepsis score and survival rate. Arbidol observably alleviates inflammatory infiltrates and injury in the lungs and liver. Finally, we also found that arbidol reduced serum levels of pro-inflammatory factors such as TNF-α and IL-6 induced by fecal dilution. In conclusion, our results indicate that arbidol can alleviate the severity of pulmonary fibrosis and sepsis, and provide some reference for the treatment of cytokine storm and sequelae of pulmonary fibrosis in patients with COVID-19.
format Online
Article
Text
id pubmed-7873045
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78730452021-02-11 Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice Li, Hailong Liu, Rui Zhang, Ruotong Zhang, Shanshan Wei, Yiying Zhang, Liang Zhou, Honggang Yang, Cheng Front Pharmacol Pharmacology From the perspective of epidemiology, viral immunology and current clinical research, pulmonary fibrosis may become one of the complications of patients with Coronavirus Disease 2019 (COVID-19). Cytokine storm is a major cause of new coronavirus death. The purpose of this study was to explore the effects of antiviral drug arbidol on cytokine storm and pulmonary fibrosis. Here, we use a mouse model of bleomycin-induced pulmonary fibrosis and a mouse model of fecal dilution-induced sepsis to evaluate the effects of arbidol on pulmonary fibrosis and cytokine storm. The results showed that arbidol significantly reduced the area of pulmonary fibrosis and improved lung function (reduced inspiratory resistance, lung dynamic compliance and forced vital capacity increased). Treatment with arbidol promoted reduced sepsis severity 48 h after sepsis induction, based on weight, murine sepsis score and survival rate. Arbidol observably alleviates inflammatory infiltrates and injury in the lungs and liver. Finally, we also found that arbidol reduced serum levels of pro-inflammatory factors such as TNF-α and IL-6 induced by fecal dilution. In conclusion, our results indicate that arbidol can alleviate the severity of pulmonary fibrosis and sepsis, and provide some reference for the treatment of cytokine storm and sequelae of pulmonary fibrosis in patients with COVID-19. Frontiers Media S.A. 2021-01-27 /pmc/articles/PMC7873045/ /pubmed/33584285 http://dx.doi.org/10.3389/fphar.2020.607075 Text en Copyright © 2021 Li, Liu, Zhang, Zhang, Wei, Zhang, Zhou and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Hailong
Liu, Rui
Zhang, Ruotong
Zhang, Shanshan
Wei, Yiying
Zhang, Liang
Zhou, Honggang
Yang, Cheng
Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
title Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
title_full Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
title_fullStr Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
title_full_unstemmed Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
title_short Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
title_sort protective effect of arbidol against pulmonary fibrosis and sepsis in mice
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873045/
https://www.ncbi.nlm.nih.gov/pubmed/33584285
http://dx.doi.org/10.3389/fphar.2020.607075
work_keys_str_mv AT lihailong protectiveeffectofarbidolagainstpulmonaryfibrosisandsepsisinmice
AT liurui protectiveeffectofarbidolagainstpulmonaryfibrosisandsepsisinmice
AT zhangruotong protectiveeffectofarbidolagainstpulmonaryfibrosisandsepsisinmice
AT zhangshanshan protectiveeffectofarbidolagainstpulmonaryfibrosisandsepsisinmice
AT weiyiying protectiveeffectofarbidolagainstpulmonaryfibrosisandsepsisinmice
AT zhangliang protectiveeffectofarbidolagainstpulmonaryfibrosisandsepsisinmice
AT zhouhonggang protectiveeffectofarbidolagainstpulmonaryfibrosisandsepsisinmice
AT yangcheng protectiveeffectofarbidolagainstpulmonaryfibrosisandsepsisinmice